Osteoarthritis is a degenerative joint disease affecting cartilage, subchondral bone, and periarticular tissues, causing pain, stiffness, and functional limitation. It is a leading cause of disability in older adults.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
Animal health markets are projected to expand in 2026, led by animal biotechnology at $34.6 billion to $36.19 billion and continued growth in veterinary antibiotics. Demand is being driven by companion animal care, livestock health, biologics R&D, and tighter oversight of antibiotic use.
Cynata raised $1.5 million through a placement at $0.25 a share ahead of Phase 3 osteoarthritis and Phase 2 aGvHD trial readouts due in May and June 2026. Its aGvHD study has completed the 100-day primary evaluation period for all 65 participants.
The healthcare 3D printing market is projected to reach $14.6 billion by 2033, while the bioinks market is anticipated to reach USD 683.6 million. Growth is tied to personalised medical solutions, tissue engineering, drug discovery, and advances in biomaterials.
Five intra-articular gene therapy platforms for knee osteoarthritis are in human trials in the US, while India prepares regulatory guidelines for mRNA, gene and cell therapies to accelerate innovation.
Semaglutide reduced osteoarthritis progression in obese mice through metabolic reprogramming of cartilage cells, independent of weight loss effects, according to research published in Cell Metabolism.
Research identifies orphan nuclear receptor SHP (NR0B2) as a novel regulator of osteoarthritis progression, demonstrating that it protects cartilage by inhibiting IKKβ/NF-κB signaling and reducing matrix-degrading enzyme expression in chondrocytes.
New research reveals semaglutide may directly repair cartilage in osteoarthritis patients, while a separate study raises concerns about SNAC, an ingredient used in oral semaglutide formulations, and its effects on gut health.
The European Commission has approved a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide injection) for adults with obesity, providing physicians with an additional treatment option for patients requiring further weight reduction after the 2.4 mg dose.
Researchers from Stanford Medicine developed an injection that reprograms cells to regrow cartilage by blocking the protein 15-PGDH, offering potential treatment for osteoarthritis from aging or injury.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07595718 |
AI-Based Phenome Data Analysis for Predicting the Onset of Major Diseases |
RECRUITING | |
| NCT07574762 |
Total Knee Arthroplasty With Personalized Implantation: Computer Navigation-Assisted Surgery Versus Robotic-Assisted Surgery |
RECRUITING | NA |
| NCT07566520 |
Prevalence of Sarcopenia and Its Associated Factors in Patients With Knee Osteoarthritis in a Tertiary Care Hospital in Upper Egypt |
NOT_YET_RECRUITING | |
| NCT07551856 |
Manual Arthroplasty Versus VELYS Robotic-Assisted Solution Functional Alignment Arthroplasty for Knee Osteoarthritis |
NOT_YET_RECRUITING | NA |
| NCT07549386 |
Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis. |
COMPLETED | PHASE3 |
| NCT07489521 |
Arthrosamid vs. Steroid for the Management of Knee Osteoarthritis |
RECRUITING | PHASE4 |
| NCT07487766 |
The Safety and Efficacy of XytriX (Umbilical Cord-Derived Mesenchymal Stem Cells) in the Treatment of Knee Osteoarthritis |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07473414 |
Synovial Tissue as a Biomarker in the Early Management of Osteoarthritis |
NOT_YET_RECRUITING | NA |
| NCT07429565 |
Testing APPA-1 in Healthy Subjects and Osteoarthritis Patients |
COMPLETED | PHASE1 |
| NCT07417891 |
Ketogenic Diet to Reduce Osteoarthritis Pain in MCI |
NOT_YET_RECRUITING | NA |
